Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients

Background. - Approximately half of cyclosporine A-treated renal transplant recipients do not reach sufficient mycophenolic acid (MPA) exposure in the first weeks posttransplantation with standard MPA dosing regimens. - Methods. - Here, we present a prospectively planned meta-analysis of data from...

Full description

Saved in:
Bibliographic Details
Main Authors: Budde, Klemens (Author) , Tedesco-Silva, Helio (Author) , Arns, Wolfgang (Author) , Shoker, Ahmed (Author) , Zeier, Martin (Author) , Klinger, Marian (Author) , Rosales, Beatriz (Author) , Walker, Rowan (Author) , Prestele, Hans (Author) , Vaidya, Soniya (Author) , Kuypers, Dirk (Author)
Format: Article (Journal)
Language:English
Published: August 15, 2011
In: Transplantation
Year: 2011, Volume: 92, Issue: 3, Pages: 321-327
ISSN:1534-6080
DOI:10.1097/TP.0b013e318223d7f3
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/TP.0b013e318223d7f3
Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/transplantjournal/Fulltext/2011/08150/Improved_Rejection_Prophylaxis_With_an_Initially.12.aspx
Get full text
Author Notes:Klemens Budde, Helio Tedesco-Silva, Wolfgang Arns, Ahmed Shoker, Martin Zeier, Marian Klinger, Beatriz Rosales, Rowan Walker, Hans Prestele, Soniya Vaidya, and Dirk Kuypers
Description
Summary:Background. - Approximately half of cyclosporine A-treated renal transplant recipients do not reach sufficient mycophenolic acid (MPA) exposure in the first weeks posttransplantation with standard MPA dosing regimens. - Methods. - Here, we present a prospectively planned meta-analysis of data from two 6-month parallel-run studies that evaluated the effect of an initially intensified versus standard dosing regimen of enteric-coated mycophenolate sodium (EC-MPS). Four hundred forty-one de novo renal transplant recipients were randomized (1:1) to intensified (2 weeks 2880 mg/d; subsequently 4 weeks 2160 mg/d; followed by 1440 mg/d) or standard (1440 mg/d) EC-MPS, with concomitant cyclosporine A treatment and steroids with or without anti-IL-2R induction. Primary endpoint was treatment failure (biopsy-proven acute rejection [BPAR], graft loss, or death) at month 6 posttransplantation. - Results. - Treatment failure rates were 17.4% in intensified and 22.4% in standard groups (P=0.110). The incidence of BPAR was 13.8% (intensified) vs. 19.3% (standard; P=0.034). A total of 80.5% (intensified) versus 39.0% (standard) of patients achieved 12 hr MPA-area under the curve more than 30 μg·hr/mL as early as day 3 posttransplant. Renal function, gastrointestinal symptom rating scores, and safety profiles were comparable between treatment groups. - Conclusion. - The initially intensified EC-MPS dosing regimen was associated with higher MPA exposure, significantly lower rate of BPAR, and comparable safety. However, the intensified regimen did not affect graft function or survival.
Item Description:Gesehen am 24.06.2022
Physical Description:Online Resource
ISSN:1534-6080
DOI:10.1097/TP.0b013e318223d7f3